GEHC Stock - GE HealthCare Technologies Inc.
Unlock GoAI Insights for GEHC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $19.67B | $19.55B | $18.34B | $17.59B | $17.16B |
| Gross Profit | $8.21B | $7.92B | $7.18B | $7.17B | $6.77B |
| Gross Margin | 41.7% | 40.5% | 39.1% | 40.8% | 39.4% |
| Operating Income | $2.63B | $2.44B | $2.52B | $2.79B | $2.72B |
| Net Income | $1.99B | $1.57B | $1.92B | $2.25B | $13.85B |
| Net Margin | 10.1% | 8.0% | 10.4% | 12.8% | 80.7% |
| EPS | $4.37 | $3.04 | $4.22 | $4.90 | $4.41 |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 13th 2025 | Barclays | Initiation | Equal Weight | $86 |
| October 7th 2025 | Citigroup | Downgrade | Neutral | $83 |
| May 5th 2025 | UBS | Upgrade | Neutral | $73 |
| March 11th 2025 | Goldman | Upgrade | Buy | $100← $85 |
| January 8th 2025 | Jefferies | Upgrade | Buy | $103← $95 |
| September 26th 2024 | UBS | Downgrade | Sell | $74← $84 |
| September 18th 2024 | BTIG Research | Upgrade | Buy | $100 |
| September 9th 2024 | JP Morgan | Initiation | Neutral | $90 |
| August 6th 2024 | Stifel | Initiation | Buy | $100 |
| May 30th 2024 | Goldman | Initiation | Neutral | $87 |
| February 15th 2024 | HSBC Securities | Initiation | Buy | $100 |
| February 12th 2024 | UBS | Upgrade | Neutral | $88← $66 |
| November 30th 2023 | Jefferies | Initiation | Hold | $80 |
| November 27th 2023 | UBS | Downgrade | Sell | $66← $86 |
| September 19th 2023 | Citigroup | Initiation | Buy | $82 |
Earnings History & Surprises
GEHCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 12, 2026 | $1.43 | — | — | — |
Q4 2025 | Oct 29, 2025 | $1.05 | $1.07 | +1.9% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.92 | $1.06 | +15.5% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $0.91 | $1.01 | +10.5% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $1.26 | $1.45 | +15.1% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $1.05 | $1.14 | +8.6% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.98 | $1.00 | +2.0% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $0.91 | $0.90 | -1.1% | ✗ MISS |
Q1 2024 | Feb 6, 2024 | $1.07 | $1.18 | +10.3% | ✓ BEAT |
Q4 2023 | Oct 31, 2023 | $0.90 | $0.99 | +10.0% | ✓ BEAT |
Q3 2023 | Jul 25, 2023 | $0.87 | $0.92 | +5.7% | ✓ BEAT |
Q2 2023 | Apr 25, 2023 | $0.79 | $0.85 | +7.6% | ✓ BEAT |
Q1 2023 | Jan 30, 2023 | — | $1.31 | — | — |
Q4 2022 | Dec 8, 2022 | — | $1.07 | — | — |
Q3 2022 | Sep 30, 2022 | — | $1.07 | — | — |
Q1 2022 | Mar 31, 2022 | — | $0.85 | — | — |
Q4 2021 | Dec 31, 2021 | — | $1.24 | — | — |
Q3 2021 | Sep 30, 2021 | — | $1.11 | — | — |
Q2 2021 | Jun 30, 2021 | — | $1.28 | — | — |
Q1 2021 | Mar 31, 2021 | — | $1.28 | — | — |
Latest News
Vaso's Unit Amends Sales Representation Deal With GE Healthcare To Extend Term Agreement Through Dec. 31, 2030
📈 PositiveReported Earlier, GE HealthCare Partners With Indonesia's Ministry Of Health To Deploy 300+ Advanced CT Scanners Nationwide
📈 PositiveCitigroup Maintains Neutral on GE HealthCare Techs, Raises Price Target to $88
➖ NeutralJefferies Maintains Buy on GE HealthCare Techs, Raises Price Target to $105
📈 PositiveGE HealthCare And Mayo Clinic Launch GEMINI-RT, Strategic Initiative To Personalize Radiation Therapy By Integrating Imaging, AI, And Patient Monitoring Across Cancer Care Continuum
📈 PositiveUniversity of Rochester Medical Center and GE HealthCare Form Care Alliance To Advance Imaging, Molecular Diagnostics, and Patient Monitoring Across UR Medicine Health System
📈 PositiveGE HealthCare Unveils Advanced Image Technologies In Partnership With Nvidia
📈 PositiveReported Sunday, GE HealthCare Launches Advanced SIGNA MRI Platforms Combining AI Workflow Precision Imaging And Helium Saving Sustainability
📈 PositiveReported Sunday, GE HealthCare Highlights AI Powered Imaging Systems And Breakthrough Photon Counting CT And MRI Technologies At RSNA 2025
📈 PositiveBTIG Reiterates Buy on GE HealthCare Techs, Maintains $87 Price Target
📈 PositiveGE HealthCare Signs Agreement To Acquire Intelerad For $2.3B In Cash
📈 PositiveGE HealthCare, DeepHealth Intend To Expand Partnership Over Further Commercialization, Adoption Of AI Across Multiple Imaging Modalities
📈 PositiveMorgan Stanley Maintains Equal-Weight on GE HealthCare Techs, Raises Price Target to $80
➖ NeutralEvercore ISI Group Maintains Outperform on GE HealthCare Techs, Raises Price Target to $92
📈 PositiveWells Fargo Maintains Overweight on GE HealthCare Techs, Lowers Price Target to $87
➖ NeutralGE HealthCare Techs Raises FY2025 Adj EPS Guidance from $4.43-$4.63 to $4.51-$4.63 vs $4.53 Est
📈 PositiveGE HealthCare Techs Q3 Adj. EPS $1.07 Beats $1.05 Estimate, Sales $5.143B Beat $5.079B Estimate
📈 PositiveGE HealthCare Receives CE Mark For Carevance Patient Monitor, Expanding Access To Advanced Monitoring Across Europe
📈 PositiveGE HealthCare Partnering With The Queen's Health Systems, Duke Health To Enhance Hospital Operations, Patient Care Through New AI-Driven Hospital Operations Platform
📈 PositiveBTIG Maintains Buy on GE HealthCare Techs, Raises Price Target to $89
📈 PositiveFrequently Asked Questions about GEHC
What is GEHC's current stock price?
What is the analyst price target for GEHC?
What sector is GE HealthCare Technologies Inc. in?
What is GEHC's market cap?
Does GEHC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GEHC for comparison